Introduction {#s0001}
============

Gastric injury is one of the world's most common diseases; it and related diseases are very difficult to completely cure. Recently, the prevalence of gastric injury is rising due to environmental factors such as the increased consumption of fatty foods, smoking, stress, alcohol, and *Helicobacter pylori* infection, nonsteroidal anti-inflammatory drugs (NSAIDs) (Satyanarayana [@CIT0035]; Kim et al. [@CIT0013]), resulting in erosion, erythema, hemorrhage, and edema (Kushima et al. [@CIT0014]; Yeo et al. [@CIT0043]). This inflammatory disease of the gastrointestinal mucous membrane is called gastritis, which is more likely to develop into chronic gastritis, (gastric ulcer) when the damage is more advanced than mucous plates (Lee et al. [@CIT0019]; Lee et al. [@CIT0018]). The secretion of gastric acid is caused by the expression of histamine 2 receptor (H2r) by histamine, activation of cholecystokinin 2 receptor (CCK2r) by gastrin, and activation of muscarinic acetylcholine receptor M3 (M3r) by acetylcholine (Lee et al. [@CIT0016]). H2r accelerates the secretion of gastric acid into the stomach lumen *via* the cAMP/protein kinase A/proton pump pathway (Takeuchi et al. [@CIT0041]). Thus, H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are considered representative of gastritis and gastric ulcers. Typical gastritis and gastric ulcer drugs include H2RAs such as ranitidine, cimetidine, and famotidine, which inhibit the secretion of gastric acid, and PPIs, such as omeprazole and pantoprazole (Park et al. [@CIT0031]). Although these drugs showed clinically excellent therapeutic effects, side effects have been reported such as digestive disorders, rashes, and urticaria (Lee et al. [@CIT0019]). Therefore, development of new drugs to treat gastritis and gastric ulcers using natural plants or herbs which have no toxicity and side effects is promising. Recently, the protective effects of herbal extracts against gastric injuries such as the protective effects of *Lycium chinense* Miller (Solanaceae) on acute gastric lesion in mice (Lee et al. [@CIT0019]) and inhibitory effects of cabbage juice on EtOH-HCl induced gastritis in rats (Hong et al. [@CIT0005]) were reported.

HemoHIM is an herbal preparation consisting of roots of *Angelica gigas* Nakai (Apiaceae), *Cnidium officinale* Makino (Umbelliferae), and *Paeonia japonica* Miyabe (Paeoniaceae) that has antioxidant and immune-modulating activities (Jo et al. [@CIT0011]; Shin et al. [@CIT0036]; Park et al. [@CIT0028]). In addition, HemoHIM can protect gastrointestinal and immune hematopoietic systems against radiation (Park et al. [@CIT0030]). In several studies, the herbal ingredients of HemoHIM, or compounds containing them, have shown protective effects against gastric injuries. Jiyu-tang containing Angelica Radix inhibits gastric and ileac mucosal ulcers induced by indomethacin (Kang et al. [@CIT0012]) and polysaccharides from Angelica Radix attenuates gastric injury, promoting normal gastric epithelial cell migration and proliferation (Lam et al. [@CIT0015]). In addition, Cnidii Rhizoma protects the stomach against ethanol (EtOH)-induced gastric injury (Shin et al. [@CIT0038]). The nine herbal mixture types containing Cnidii Rhizoma exert antimicrobial and antioxidant activities against *Helicobacter pylori* (Park and Kim [@CIT0029]). Paeonia Radix protects the gastric mucosa from oxidative stress caused by acidified EtOH and compound 48/80 (Ohta et al. [@CIT0025]; Kim et al. [@CIT0013]). In addition, the antioxidant and inhibitory effects on *Helicobacter pylori* have been found in beverages containing Angelica Radix, Cnidii Rhizoma and Paeonia Radix (Park [@CIT0032]). HemoHIM alleviated airway inflammation (Shin et al. [@CIT0037]) and had the anti-inflammatory effects in colitis (Lee et al. [@CIT0017]). Thus, HemoHIM may be a good candidate for treatment and prevention of gastritis and gastric ulcers, due to the excellent effects of the herbal ingredients.

The NSAID indomethacin-induced bleeding, ulcers, and erosions in the gastrointestinal tract in both animal and human trials (Djahanguiri [@CIT0004]). In addition, EtOH/HCl causes severe damage and necrotic lesions to the gastric mucosa (Hong et al. [@CIT0005]). The animal models of gastric injuries induced by indomethacin and EtOH/HCl have been widely used in studies to evaluate the protective effects of herbal products against gastritis and gastric ulcers. Sreeja et al. ([@CIT0039]) and de Araújo et al. ([@CIT0003]) studied the gastroprotective action of *Sphenodesme involucrata* var. *paniculata* (C. B. Clarke) Munir (Lamiaceae), *Kalanchoe brasiliensis* Cambess (Crassulaceae), and *Kalanchoe pinnata* (Lamarck) Persoon (Crassulaceae) leaf juices using EtOH, EtOH/HCl-, and indomethacin-induced experimental gastric ulcer models. Therefore, in the present study, the protective effects of HemoHIM against indomethacin- and EtOH/HCl-induced gastric mucosal injury in rat models were investigated.

Materials and methods {#s0002}
=====================

Materials {#s0003}
---------

Formalin, indomethacin, cimetidine, sodium carbonate, Tween 80, ethanol (EtOH), carboxymethyl cellulose (CMC), and phosphoric acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). The reference standards, chlorogenic acid was purchased from USP reference standard (Rockville, MD, USA), paeoniflorin and nodakenin were purchased from Wako Pure Chemical Industries (Osaka, Japan). HPLC-grade methanol and water were purchased from Honeywell, Burdick & Jackson (Muskegon, MI, USA). Phosphate buffered saline (PBS) was purchased from Gibco (Grand Island, NY, USA), HCl was purchased from Daejung Chemicals (Gyeonggi-do, Republic of Korea), and sodium hydroxide was purchased from Duksan Pure Chemical (Gyeonggi-do, Republic of Korea).

Preparation of HemoHIM {#s0004}
----------------------

HemoHIM was prepared according to the method described in detail in our previous report (Jo et al. [@CIT0011]). The standardized HemoHIM (Batch no: HHH009) containing nodakenin (50-150 mg/100 g), chlorogenic acid (25--60 mg/100 g), and paeoniflorin (200--400 mg/100 g) was manufactured by Kolmar BNH (Sejong-si, Republic of Korea). Briefly, traditional Korean medicinal plants, *Angelica gigas*, *Cnidium officinale*, and *Paeonia japonica* were extracted for 4 h in boiling water to obtain a total extract. Half of the extract was precipitated with 95% EtOH to obtain an EtOH-insoluble polysaccharide fraction. Finally, the HemoHIM was obtained by adding the polysaccharide fraction to the remaining half of the extract, concentrated to a solid content of 30% ± 3%, freeze-dried (MCFD8512, Ilshin Lab, Seoul, Republic of Korea) and stored at 4 °C until use.

HPLC analysis {#s0005}
-------------

The analyses were performed using an HPLC system (Prominence HPLC system, Shimadzu, Kyoto, Japan) with Capcell Pak C18 column (4.6 × 250 mm^2^, 5 μm, Shiseido, Tokyo, Japan). The mobile phase included 0.1% phosphoric acid in water (Solvent A) and 0.1% phosphoric acid in acetonitrile (Solvent B). The flow rate was set at 1.0 mL/min and column temperature was kept at 30 °C. The auto-sampler was conditioned at 4 °C and the injection volume was 10 μL. The UV detector wavelength was set at 230 nm. The reference standards of chlorogenic acid, paeoniflorin, and nodakenin were accurately weighed, dissolved in 80% methanol, and then diluted to appropriate concentration ranges for the establishment of calibration curves. HemoHIM was dissolved in 50 volumes (w/v) of 80% methanol and then filtered through a 0.45 μm PVDF filter membrane (Chromdisc, Daegu, Korea). The filtrate was injected into the HPLC system.

Animals and experimental protocol {#s0006}
---------------------------------

Male Sprague Dawley (SD) rats 5- and 6-weeks-old were used for indomethacin-induced (five groups of ten) and EtOH/HCl-induced models (five groups of ten), respectively. Rats were purchased from DooYeol Biotech (Seoul, Republic of Korea) and housed in a controlled environment (25 °C ± 2 °C, 55% ± 5% relative humidity under a 12 h light-dark cycle). Throughout the experiment, the rats were allowed free access to food and tap water. All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Korea Kolmar Animal Ethics Committee (18-KBH-I-01).

Indomethacin-induced gastric ulcer model {#s0007}
----------------------------------------

Rats were divided into five groups: control, indomethacin, HemoHIM 250 mg kg^−1^, HemoHIM 500 mg kg^−1^, and cimetidine 100 mg kg^−1^. HemoHIM (250, 500 mg kg^−1^) dissolved in 0.5% CMC or cimetidine (100 mg kg^−1^) dissolved in 20% Tween 80, were administered orally after 24 h of fasting. Indomethacin (80 mg kg^−1^) dissolved in 5% sodium bicarbonate was administered orally 1 h after the administration of HemoHIM or cimetidine. Three hours after administration of indomethacin, rats were anesthetized and euthanized. The inner and outer layers of the gastric wall were fixed with 4% neutral formalin. After 30 min, the stomachs were dissected and washed with PBS.

EtOH/HCl-induced gastritis model {#s0008}
--------------------------------

Rats were divided into five groups: control, EtOH/HCl, HemoHIM 250 mg kg^−1^, HemoHIM 500 mg kg^−1^, and cimetidine 100 mg kg^−1^. HemoHIM (250 or, 500 mg kg^−1^) dissolved in 0.5% CMC or cimetidine (100 mg kg^−1^) dissolved in 20% Tween 80, were administered orally after 24 h of fasting. Next, 60% EtOH/150 mM HCl was administered orally 1 h after the administration of HemoHIM or cimetidine. One hour after administration of 60% EtOH/150 mM HCl, rats were dissected. The gastric juice was centrifuged at 3,000 rpm for 20 min and the total acidity was assayed (Nam et al. [@CIT0024]). Briefly, 0.5% dimethylaminobenzene alcohol solution and 1% phenolphthalein alcohol solution were added to the gastric juice supernatant. The solution was titrated by adding 0.1 N NaOH solution until the red color disappeared. The total acidity of the titration value is expressed as meq/L/100 g using the following formula: Acidity = (Volume of NaOH × Normality of NaOH × 100)/0.1 (meq/L).

Analysis of gastric lesions {#s0009}
---------------------------

For the determination of gastric lesion area, the inner surface of the stomach was photographed and analyzed using Image J software (NIH ImageJ, NIH, Bethesda, MD). Lesion area (%) was determined for the lesion area of the stomach tissue. The inhibition ratio was calculated as follows: Inhibition ratio (%) = {(control lesion area - sample lesion area)/control lesion area}) × 100. For histopathological analysis, the stomachs were fixed in 10% neutral formalin and fixed overnight. Sections of the gastric glands were sliced at a thickness of 5 μm and stained with hematoxylin and eosin (H&E). The stained sections were examined under microscope for any damage or change in morphology of the particular tissue.

Statistical analysis {#s0010}
--------------------

The results are presented as the mean ± standard error or the mean (S.E.M). One-way analysis of variance (ANOVA) followed by Duncan's multiple range test used for comparing three or more groups. The GraphPad Prism5.0 (GraphPad Prism Software, San Diego, CA) program was used for statistical analysis. *p* values \< 0.05 were considered statistically significant.

Results {#s0011}
=======

Identification and quantification of chlorogenic acid, paeoniflorin, and nodakenin using HPLC {#s0012}
---------------------------------------------------------------------------------------------

The main compounds in the standardized composition of HemoHIM were investigated using HPLC at 230 nm ([Figure 1](#F0001){ref-type="fig"}). The identified compounds in HemoHIM included chlorogenic acid (retention time: 22.488 min), paeoniflorin (retention time: 26.880 min), and nodakenin (retention time: 32.061 min). The quantities of chlorogenic acid, paeoniflorin, and nodakenin were 37, 358, and 106 mg/100 g, respectively. Thus, this batch of HemoHIM was found to contain the compounds within the range of the production management standards of chlorogenic acid (25--60 mg/100 g), paeoniflorin (200--400 mg/100 g), and nodakenin (50--150 mg/100 g).

![HPLC chromatogram of HemoHIM. Peak number indicated: 1: chlorogenic acid, 2: paeoniflorin, 3: nodakenin.](IPHB_A_1651875_F0001_B){#F0001}

HemoHIM inhibits the reddening and hemorrhage in indomethacin-induced gastric ulcer model {#s0013}
-----------------------------------------------------------------------------------------

First, the protective role of HemoHIM against indomethacin-induced ulcers was investigated using rats. The body weights were not significantly different between the groups ([Table 1](#t0001){ref-type="table"}). Gross findings of the rats in the indomethacin group showed numerous large lesions in the entire gastric mucosa such as signs of clear reddening and hemorrhage compared with the rats in the control group (arrow heads in [Figure 2(B))](#F0002){ref-type="fig"}. However, pretreatment with HemoHIM significantly decreased reddening and hemorrhage ([Figures 2(C,D))](#F0002){ref-type="fig"}. HemoHIM showed significant inhibition of gastric injury in indomethacin-induced model (250 mg kg^−1^; 64.30% ± 8.98% and 500 mg kg^−1^; 67.75% ± 5.33%, *p* \< 0.001, respectively) compared to indomethacin group. Inhibition ratio in the cimetidine 100 mg kg^−1^ was 94.07% ± 2.37% (*p* \< 0.001) ([Figure 3](#F0003){ref-type="fig"}, [Table 2](#t0002){ref-type="table"}).

![Effect of HemoHIM on stomach appearance in indomethacin-induced rat. Arrow heads indicate reddening and hemorrhage.(A) Control (B) Indomethacin (C) HemoHIM 250 mg kg^−1^ (D) HemoHIM 500 mg kg^−1^ (E) Cimetidine 100 mg kg^−1^.](IPHB_A_1651875_F0002_C){#F0002}

![Effect of HemoHIM on inhibition ratio (%) in indomethacin-induced rats. Data are expressed as mean ± SEM (*n* = 10). Comparison was made between indomethacin and each sample treatment group. Significant differences as compared with indomethacin group (\*\*\**p* \< 0.001).](IPHB_A_1651875_F0003_B){#F0003}

###### 

Number of animals and body weight on indomethacin and EtOH/HCI-induced gastric mucosal injury models.

  Group                        Animals            No. of animals   Body weight (g)
  ---------------------------- ------------------ ---------------- -----------------
  Indomethacin-induced model                                        
   Control                                        10               153.60 ± 2.88
   Indomethacin                                   10               152.55 ± 2.50
   HemoHIM 250                 SD-rat, 5w, male   10               152.33 ± 2.96
   HemoHIM 500                                    10               151.64 ± 2.30
   Cimetidine                                     10               155.07 ± 4.58
  EtOH/HCI-induced model                                            
   Control                                        10               226.43 ± 3.12
   Et/OH/HCI                                      10               224.10 ± 2.56
   HemoHIM 250                 SD-rat, 6w, male   10               221.96 ± 1.92
   HemoHIM 500                                    10               223.38 ± 2.65
   Cimetidine                                     10               224.64 ± 3.17

###### 

Effect of HemoHIM on lesion area (%) in indomethacin and EtOH/HCI-induced rats.

  Group                              Lesion area (%)
  ---------------------------------- --------------------
  Indomethacin-induced ulcer model    
   Control                           0
   Indomethacin                      10.11 ± 1.57
   HemoHIM 250                       4.03 ± 1.10\*\*
   HemoHIM 500                       3.49 ± 0.79\*\*\*
   Cimetidine                        0.27 ± 0.05\*\*\*
  EtOH/HCI-induced gastritis model    
   Control                           0
   Et/OH/HCI                         25.69 ± 2.65
   HemoHIM 250                       10.12 ± 1.74\*\*\*
   HemoHIM 500                       5.92 ± 1.00\*\*\*
   Cimetidine                        7.64 ± 0.90\*\*\*

Lesion area (%) indicates the damaged area. Thus, HemoHIM significantly reduced damaged area compared to the induction group (indomethacin and EtOH/HCl group). Significant differences as compared with indomethacin group and EtOH/HCl group (\*\**p* \< 0.01, \*\*\**p* \< 0.001).

HemoHIM suppresses lesions and total gastric acidity in EtOH/HCl-induced gastritis model {#s0014}
----------------------------------------------------------------------------------------

HemoHIM showed significant inhibition of gastric injury in EtOH/HCl-induced model (250 mg kg^−1^; 61.05% ± 7.22% and 500 mg kg^−1^; 73.37% ± 7.12%, *p* \< 0.001, respectively) compared to EtOH/HCl group. Inhibition ratio in the cimetidine 100 mg kg^−1^ was 94.07% ± 2.37% (*p* \< 0.001) ([Figure 4](#F0004){ref-type="fig"}, [Table 2](#t0002){ref-type="table"}). Next, whether the protective effects of HemoHIM against EtOH/HCl-induced gastritis resulted from regulating gastric acidity was examined. In the EtOH/HCl group, the gastric acidity increased to 100.40 ± 17.22 meq L^−1^ compared with the control group (28.20 ± 3.50 meq L^−1^). However, the HemoHIM treatment groups showed significantly decreased acidity to 37.80 ± 8.79 meq L^−1^ in the 250 mg kg^−1^ group (*p* \< 0.01) and to 45.20 ± 7.76 meq L^−1^ in the 500 mg kg^−1^ group (*p* \< 0.001) ([Figure 4(B))](#F0004){ref-type="fig"}.

![Effect of HemoHIM on stomach appearance and the changes of secretion of gastric acid in EtOH/HCl induced rats. (A) Inhibition ratio (%) (B) Acidity (meq/L). Data are expressed as mean ± SEM (*n* = 10). Comparison was made between EtOH/HCl and each sample treatment group. Significant difference as compared with EtOH/HCl group (\*\**p* \< 0.01, \*\*\**p* \< 0.001).](IPHB_A_1651875_F0004_B){#F0004}

HemoHIM inhibits gastric lesions including erosion and hemorrhage in EtOH/HCl-induced gastritis model based on histopathological analysis {#s0015}
-----------------------------------------------------------------------------------------------------------------------------------------

Next, the protective effects of HemoHIM in EtOH/HCl-induced gastritis model were investigated. The body weights were not significantly different between the groups ([Table 1](#t0001){ref-type="table"}). Based on histopathological examination, the rats in the control group showed smooth and clear gastric mucosa. However, in the EtOH/HCl group, the rats showed significant pathological changes such as erosion, hemorrhage and loose cell arrangement (arrow heads in [Figure 5](#F0005){ref-type="fig"}). In contrast, the rats in the HemoHIM 250, 500 mg kg^−1^, and cimetidine group showed less erosion and hemorrhage compared to the EtOH/HCl group, indicating that HemoHIM and cimetidine are effective in inhibiting gastric damage.

![Hematoxylin-eosin (H&E) staining of histological section of the gastric mucosa in the gastric glands in EtOH/HCl-induced rats. Arrow heads indicate erosion and hemorrhage. (A) Control (B) EtOH/HCl (C) HemoHIM 250 mg kg^−1^ (D) HemoHIM 500 mg kg^−1^ (E) Cimetidine 100 mg kg^−1^.](IPHB_A_1651875_F0005_C){#F0005}

Discussion {#s0016}
==========

Gastritis and gastric ulcer are common diseases worldwide, and the incidence is rising among not only adults but also children and minors (Zhao et al. [@CIT0044]). Major causes include *Helicobacter pylori* infection, overuse of NSAIDs, alcohol consumption, stress, and irregular eating habits (Lee et al. [@CIT0019]). Gastritis is an inflammation disease in all parts of the stomach that causes trimming, nausea, indigestion, and heartburn (Hong et al. [@CIT0006]). The stimulated gastric acid secretion increases internal pH and gastric mucosal damage (Nam et al. [@CIT0024]). The gastritis symptoms can progress further to damage of submucosa or muscular layers in the stomach wall, which is called a gastric ulcer. The ulcer does not occur in normal mucosa and is associated with diffuse gastritis (Jee [@CIT0009]; Lee et al. [@CIT0019]). Gastric ulcers resulting from NSAID use are caused by gastric mucosal cell damage due to the increase of mucosal permeability of active radicals, decrease of blood flow, and damage of vascular endothelial cells resulting from changes in blood cell functions (Lee et al. [@CIT0016]). PPIs such as omeprazole, pantoprazole, and rabeprazole as well as H2RAs including cimetidine, ranitidine, famotidine, and misoprostol, have been developed to treat the symptoms caused by NSAIDs, however, these drugs have various side effects such as diarrhea, nausea, stomachache, and skin rash (Miederer [@CIT0022]; Lim et al. [@CIT0020]). NSAIDs have been shown to damage the mucosa membrane and weaken the mucosal resistance (Satyanarayana [@CIT0035]). Indomethacin, a first generation NSAID, damages gastric mucosa by inhibiting of cyclooxygenase (COX), thus, limiting synthesis of prostaglandins (PGs) (Takeuchi et al. [@CIT0042]; Sagar and Ahamed [@CIT0034]). Indomethacin suppresses both isoforms of the COX enzyme (COX-1 and COX-2), induces severe damage in gastric tissue accompanied by gastrointestinal bleeding (Peskar et al. [@CIT0033]; Suleyman et al. [@CIT0040]). In addition, results from several studies indicated that indomethacin induces lipid peroxidation and has pro-oxidant activity by generating ROS (Takeuchi et al. [@CIT0042]; Miura et al. [@CIT0023]). To assess the protective effects of HemoHIM against gastric damage caused by NSAIDs, the indomethacin-induced gastric damage model was used according to previous studies (Babyatsky et al. [@CIT0002]; Ji and Baek [@CIT0010]). The reduction of lesion area is the most direct indicator of treatment effectiveness for gastric injury. In the present study, the increased lesion area caused by indomethacin was significantly reduced by administration of HemoHIM, which is a direct result of suppressing gastric damage. Based on the antioxidant effect of HemoHIM\'s previous study, HemoHIM potentially inhibited gastric injury by inhibiting ROS (Shin et al. [@CIT0036]).

Gastric injury caused by EtOH/HCl is a widely used gastritis model in which EtOH directly stimulates the gastric mucosa to remove free antioxidants, thereby increasing free radicals, lipid peroxidation, and PG, further exacerbating acute gastritis (Ishii et al. [@CIT0008]; Anandan et al. [@CIT0001]; Sreeja et al. [@CIT0039]). In the EtOH/HCl-induced gastric injury rat model experiments performed in the present study, the area of gastric lesions was reduced in HemoHIM and cimetidine groups compared with the EtOH/HCl group. Histopathological analysis showed hemorrhage and erosion in EtOH/HCl group, however, the incidence of damage was lower in HemoHIM and cimetidine groups than in the EtOH/HCl group. The results obtained with HemoHIM are similar to previous results that showed rats with EtOH/HCl-induced acute gastric lesions recovered normal mucosal structure after being fed soy skim milk fermented by lactic acid bacteria (Liu et al. [@CIT0021]). Gastric acid secretion is an important factor in gastric damage (Okcu et al. [@CIT0027]). Gastric fluid in healthy people is controlled by normal secretion which is necessary for food digestion, however, stimulation by chemicals due to mucous membrane damage or blood flow disorder promotes gastric acid secretion (Okabe et al. [@CIT0026]). In experiments in this study, gastric acidity was increased due to stimulation with EtOH/HCl, but suppressed by the administration of HemoHIM and cimetidine. The H2RA cimetidine is a drug that inhibits the secretion of gastric acid in the stomach *via* nerve stimulation by directly antagonizing the histamine receptor of cell walls (Hung and Lee [@CIT0007]). Further studies are needed to determine whether HemoHIM acts as an H2RA inhibiting histamine secretion, or as an H^+^/K^+^ ATPase inhibitor. HemoHIM has previously been shown to have antioxidant properties (Shin et al. [@CIT0036]) and anti-inflammatory effects on epithelium in the colon mucosa of TNBS-treated rats (Lee et al. [@CIT0017]). Therefore, HemoHIM could effectively suppress the damage by eliminating the free radicals which can directly cause injury.

In the present study, the effects of HemoHIM on gastric mucosal injury induced by indomethacin and EtOH/HCl were investigated. In both models, HemoHIM had significant effects compared with cimetidine, a well-known drug for gastritis and gastric ulcers, in the gastric lesion index and gastric acid secretary parameters. Further studies on the key regulation targets of HemoHIM in these models and the effects of HemoHIM on chronic gastritis in animal models will be required to confirm the effectiveness of HemoHIM as a preventive or treatment drug against gastric injuries.

Conclusions {#s0017}
===========

The results from this study demonstrated that oral administration of HemoHIM protected against indomethacin- and EtOH/HCl-induced gastric mucosal injuries in rat models. HemoHIM inhibited pathological changes including lesion area, acidity, erosion, and hemorrhage induced by indomethacin or EtOH/HCl. These findings strongly suggest that HemoHIM is potential candidate for the treatment of gastritis and gastric ulcers. However, further studies are necessary to analyze proinflammatory cytokines and identify the molecular mechanism underlying the treatment efficacy of HemoHIM in gastritis and gastric ulcers.
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